232 related articles for article (PubMed ID: 20213306)
1. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.
Groessl M; Tsybin YO; Hartinger CG; Keppler BK; Dyson PJ
J Biol Inorg Chem; 2010 Jun; 15(5):677-88. PubMed ID: 20213306
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.
Wu K; Luo Q; Hu W; Li X; Wang F; Xiong S; Sadler PJ
Metallomics; 2012 Feb; 4(2):139-48. PubMed ID: 22262368
[TBL] [Abstract][Full Text] [Related]
3. Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.
Wu K; Hu W; Luo Q; Li X; Xiong S; Sadler PJ; Wang F
J Am Soc Mass Spectrom; 2013 Mar; 24(3):410-20. PubMed ID: 23404464
[TBL] [Abstract][Full Text] [Related]
4. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
Groessl M; Zava O; Dyson PJ
Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
[TBL] [Abstract][Full Text] [Related]
5. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
Casini A; Guerri A; Gabbiani C; Messori L
J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
[TBL] [Abstract][Full Text] [Related]
6. A mass spectrometric investigation of non-covalent interactions between ruthenium complexes and DNA.
Urathamakul T; Beck JL; Sheil MM; Aldrich-Wright JR; Ralph SF
Dalton Trans; 2004 Sep; (17):2683-90. PubMed ID: 15514752
[TBL] [Abstract][Full Text] [Related]
7. Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide.
Williams JP; Lough JA; Campuzano I; Richardson K; Sadler PJ
Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3563-9. PubMed ID: 19844963
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
[TBL] [Abstract][Full Text] [Related]
9. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
Casini A; Gabbiani C; Michelucci E; Pieraccini G; Moneti G; Dyson PJ; Messori L
J Biol Inorg Chem; 2009 Jun; 14(5):761-70. PubMed ID: 19288144
[TBL] [Abstract][Full Text] [Related]
10. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the binding of metal complexes to duplex and quadruplex DNA.
Talib J; Green C; Davis KJ; Urathamakul T; Beck JL; Aldrich-Wright JR; Ralph SF
Dalton Trans; 2008 Feb; (8):1018-26. PubMed ID: 18274682
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.
Herman A; Tanski JM; Tibbetts MF; Anderson CM
Inorg Chem; 2008 Jan; 47(1):274-80. PubMed ID: 18062685
[TBL] [Abstract][Full Text] [Related]
13. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
[TBL] [Abstract][Full Text] [Related]
14. Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.
Wang F; Xu J; Wu K; Weidt SK; Mackay CL; Langridge-Smith PR; Sadler PJ
Dalton Trans; 2013 Mar; 42(9):3188-95. PubMed ID: 23076358
[TBL] [Abstract][Full Text] [Related]
15. Transition Metal-based Anticancer Drugs Targeting Nucleic Acids: A Tandem Mass Spectrometric Investigation.
Eberle RP; Hari Y; Schürch S
Chimia (Aarau); 2017 Mar; 71(3):120-123. PubMed ID: 28351457
[TBL] [Abstract][Full Text] [Related]
16. A highly flexible dinuclear ruthenium(II)-platinum(II) complex: crystal structure and binding to 9-ethylguanine.
van der Schilden K; Garcìa F; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
Angew Chem Int Ed Engl; 2004 Oct; 43(42):5668-70. PubMed ID: 15495144
[No Abstract] [Full Text] [Related]
17. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.
Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL
J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255
[TBL] [Abstract][Full Text] [Related]
18. Titanocene binding to oligonucleotides.
Eberle RP; Schürch S
J Inorg Biochem; 2018 Jul; 184():1-7. PubMed ID: 29635096
[TBL] [Abstract][Full Text] [Related]
19. Probing DNA selectivity of ruthenium metallointercalators using ESI mass spectrometry.
Beck JL; Gupta R; Urathamakul T; Williamson NL; Sheil MM; Aldrich-Wright JR; Ralph SF
Chem Commun (Camb); 2003 Mar; (5):626-7. PubMed ID: 12669857
[TBL] [Abstract][Full Text] [Related]
20. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
